Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47

Summary

The main aim of this clinical study is to investigate the safety and tolerability of different dose strengths of IC47 up to 6 months after the first vaccination. A total of 32 healthy subjects (male or female) will participate in this clinical study. The subjects will be divided into 4 groups of 8 subjects each. Thirty (30) μg or 150 μg of IC47 will be administered three times in intervals of 42 days each.

Timeline

Start

2009-03

Primary completion

2010-02

Completion

2010-02

Drugs

Indications